Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

KEYNOTE-061 investigators

Research output: Contribution to journalArticlepeer-review

378 Citations (Scopus)

Fingerprint Dive into the research topics of 'Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences